WallStSmart

ResMed Inc (RMD)vsZEN Graphene Solutions Ltd (ZTEK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 572414% more annual revenue ($5.40B vs $942,880). RMD leads profitability with a 27.5% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

ZTEK

Avoid

23

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -5.63
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Intrinsic value data unavailable for ZTEK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

ZTEK2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
73.1%10/10

Revenue surging 73.1% year-over-year

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

ZTEK4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$63.02M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-56.6%2/10

ROE of -56.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : ZTEK

The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : ZTEK

The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

RMD profiles as a mature stock while ZTEK is a hypergrowth play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

ZTEK is growing revenue faster at 73.1% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 23/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

ZEN Graphene Solutions Ltd

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ZEN Graphene Solutions Ltd (ZTEK) is a pioneering company in the field of materials technology, dedicated to the development and commercialization of graphene-based solutions that enhance a wide array of industrial applications. With its innovative proprietary extraction techniques, ZTEK produces high-purity graphene from natural graphite, aiming to revolutionize sectors such as environmental remediation, energy storage, and advanced manufacturing. The company’s robust focus on sustainability and continuous investment in research and development underscores its commitment to leading the graphene technology market. As ZTEK navigates opportunities for growth and innovation, it stands well-positioned to drive long-term shareholder value and meet the rising global demand for high-performance materials.

Visit Website →

Want to dig deeper into these stocks?